ALX Oncology

#ICYMI: During today’s R&D Day webcast, we highlighted updates on our ongoing evorpacept clinical development program, including progress of ongoing trials and introduction of new trials in breast and colorectal cancer indications, the addition of our novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, and business and financial updates. Read more here: bit.ly/4hb07Ub #Cancer #ADC #CD47 #InvestorDay

We hope you’ll join us for our virtual R&D Day on March 5 at 6am PT/ 9am ET. During this webcast we’ll discuss our #clinical program progress and our lead investigational CD47-blocker, evorpacept, and share business and financial updates. Register here: bit.ly/3Qox18L #CD47 #Oncology #InvestorDay

We’re excited to share the launch of our redesigned website! We’ve updated our site to include our most recent clinical and pipeline updates and corporate news, and showcase how we are working to advance therapies that boost the immune system to treat cancer and extend patients’ lives – all with a modern design and an infusion of our inventive company personality. Check it out: https://alxoncology.com/

#ICYMI: ALX Oncology’s CD47 blocker is making waves with promising, updated Phase 2 data in HER2-positive gastric and gastroesophageal junction (GEJ) cancer. Check out a recent article in Scrip that highlights how our investigational therapy has now become the only CD47 agent to demonstrate both durable improvement in overall response rate and a well-tolerated safety profile in a prospective randomized study. Kohei Shitara, M.D., presented the updated data from ALX Oncology’s Phase 2 ASPEN-06 trial at #ASCO #GI25. Read more: https://bit.ly/42NOtLi #Oncology #Immunotherapy #GastricCancer #Biotech #Cancer #ClinicalTrial

ALX Oncology is excited to share positive updated results from the ASPEN-06 Phase 2 trial, building upon previously announced topline findings. The results presented today at 2025 ASCO GI highlight the first CD47 blocker to demonstrate substantial tumor response and a well-tolerated safety profile in a prospective randomized trial. It represents a significant milestone in advancing treatment options for patients with HER2-positive gastric and gastroesophageal junction cancer. Read more: https://bit.ly/4jl88Ie #Cancer #Oncology #ClinicalTrial #GI25

We’re thrilled to announce the appointment of Harish Shantharam, CFA, as our new Chief Financial Officer. With deep expertise in financial strategy and operational excellence, Harish will play a key role in guiding ALX through our next phase of growth and innovation.?? ? Additionally, we are honored to welcome two remarkable individuals to our Board of Directors:? ???Barbara Klencke,?MD,?bringing a wealth of experience in biopharmaceutical drug development, and? ???Chris Takimoto, MD, PhD, whose accomplished career in oncology drug development will help guide our journey forward ? These appointments underscore our commitment to fostering exceptional leadership as we continue driving innovation in the fight against cancer. Please join us in welcoming Harish, Barbara and Chris to the ALX Oncology family! Read the release: https://lnkd.in/gnPud4gF ? #Leadership #Oncology #TeamGrowth

Join us this Thursday, January 23 at 1PM PT / 4PM ET for a virtual company conference call and webcast highlighting updated data from our ASPEN-06 Phase 2 trial. During the call, the ALX Oncology leadership team will review the updated data presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Register here: https://bit.ly/42t2Ww9 #GastricCancer #CancerResearch #GI25

Don't miss our presentation at the 43rd Annual J.P. Morgan Healthcare Conference next week! Our CEO Jason Lettmann will present on ALX Oncology's progress and anticipated milestones for this year. Register for the webcast here: https://bit.ly/3PsB5o6

We are?pleased?to announce that updated results from the randomized Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. #GI25 Details can be found here: https://bit.ly/41HKTlg

Join us next week for our virtual company event! Our CEO, Jason Lettmann, and CMO, Alan Sandler, MD, will be joined by leading breast cancer medical oncologist, Dr. Alberto J. Montero, University Hospitals, to discuss the first data from a Phase 1b/2 clinical trial evaluating the company’s investigational CD47-blocker evorpacept in combination with zanidatamab in heavily pretreated patients with metastatic breast cancer. View today's press release and learn how to register: https://bit.ly/41vOwLd